Kiora Pharmaceuticals, Inc..
KPRX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Kiora Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of retinal diseases. Their pipeline includes investigational products targeting unmet needs in ophthalmology, such as treatments...Show More
Better Health for All
0
No evidence available to assess Kiora Pharmaceuticals, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Kiora Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess Kiora Pharmaceuticals, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Kiora Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
Kiora Pharmaceuticals restated its 2020 and 2021 financial statements on July 7, 2022, to correct misstatements related to contingent consideration, goodwill, and in-process R&D valuation for three acquisitions.
1
This averages to 0.4 restatements per year over the past five years.
2
The company has a Code of Ethics and Business Conduct.
3
The board consists of seven members, with four identified as independent directors, resulting in approximately 57% independent board members. The Audit Committee Charter outlines the committee's responsibilities regarding financial reporting, internal controls, and auditor oversight, including reviewing related party transactions.
4
Kind to Animals
-70
Kiora Pharmaceuticals, Inc. (KPRX.US) explicitly relies on animal studies for drug testing, as evidenced by its statement regarding the use of animals for KIO-201 development.
1
There is no indication that the company employs validated non-animal testing methods for product safety and efficacy.
2
Furthermore, Kiora Pharmaceuticals has not disclosed any formal policy regarding animal testing, suggesting an absence of public commitments to restrict or reduce such practices.
3
No War, No Weapons
0
No information was found in the provided articles regarding Kiora Pharmaceuticals, Inc.'s involvement in arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, or any other activities related to the 'No War, No Weapons' ethical value. The articles discuss general trends in military spending and defense contracting but do not mention Kiora Pharmaceuticals, Inc. specifically in this context. The only article mentioning the company details an employee separation agreement, which is not relevant to this assessment.
1
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative, or qualitative data regarding Kiora Pharmaceuticals, Inc.'s performance on any of the planet-friendly business metrics.
1
While some articles discuss general industry trends related to sustainable manufacturing, supply chain environmental impact, environmental regulations, climate change, and sustainable packaging, they explicitly state that no quantitative data specific to Kiora Pharmaceuticals, Inc. is provided.
2
Therefore, no KPIs can be scored based on the available evidence.
Respect for Cultures & Communities
0
Kiora Pharmaceuticals has 11 formal partnerships with patient advocacy groups through its participation in the RARE-X Vision Consortium.
1
The company's name, "Kiora," is derived from the Māori phrase "Kia ora," meaning "have life" or "be healthy," and no cultural appropriation incidents have been reported.
2
The company made a charitable contribution to the Choroideremia Research Foundation to support the strategic development of KIO-301, but the percentage of revenue donated to cultural heritage organizations is not specified.
3
FPIC processes are not applicable to the company's operations.
Safe & Smart Tech
0
No evidence available to assess Kiora Pharmaceuticals, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-40
Kiora Pharmaceuticals achieved a 94% pharmaceutical waste neutralization efficiency in 2023.
1
The company has set a target to reduce waste generation by 25% by 2025, aiming for an annual waste generation of 3.4 metric tons.
2
Additionally, the company reported no regulatory actions or violations related to waste disposal in its financial summary for the year ending December 31, 2024.
3